Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sneha Rathi

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2024
Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain TumorsSneha Rathi, Ju-Hee Oh, Wenjuan Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS TumorsSneha Rathi, Ann C Mladek, Ju-Hee Oh, et al.
Molecular Cancer Therapeutics|November 19, 2024
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628Darwin A Garcia, Sneha Rathi, Margaret A Connors, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma ModelsSonia Jain, Jessica I Griffith, Kendra A Porath, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2024
Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain TumorsSneha Rathi, Ju-Hee Oh, Wenjuan Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 16, 2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS TumorsSneha Rathi, Ann C Mladek, Ju-Hee Oh, et al.
Molecular Cancer Therapeutics|November 19, 2024
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628Darwin A Garcia, Sneha Rathi, Margaret A Connors, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma ModelsSonia Jain, Jessica I Griffith, Kendra A Porath, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Pageof 2